| Ytd | 292.35% | |
| 1y | 190.87% |
| Open | 50.61 | Prev Close | 50.61 | Low | 50.24 | High | 54.29 | Mkt Cap | 3.84B |
| Vol | 867.54K | Avg Vol | 480.73K | EPS | -1.17 | P/E | N/A | Forward P/E | -46.71 |
| Beta | 1.63 | Short Ratio | 7.58 | Inst. Own | 15.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 41.77 | 200-d Avg | 25.64 | 1yr Est | 50.80 |
PLSE News
On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distri
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse⢠technology using proprietar
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary N
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPu
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orche
An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in pa
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula
Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Deutsche Bank AG purchased a new stake in Pulse Biosciences, Inc (NASDAQ: PLSE) in the second quarte
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m
Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during tra
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets
WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ra
Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's
Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rati
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a p
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy a
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinica
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Con
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 20
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ techn
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analys
The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Ark
Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanos
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprieta
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analys
Pulse Biosciences stock rises after new study data showed strong early results for its heart treatme
Pulse Biosciences stock trading higher on promising clinical data for atrial fibrillation treatment,
U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.
